MX2021015942A - Composiciones y métodos para tratar trastornos del snc. - Google Patents
Composiciones y métodos para tratar trastornos del snc.Info
- Publication number
- MX2021015942A MX2021015942A MX2021015942A MX2021015942A MX2021015942A MX 2021015942 A MX2021015942 A MX 2021015942A MX 2021015942 A MX2021015942 A MX 2021015942A MX 2021015942 A MX2021015942 A MX 2021015942A MX 2021015942 A MX2021015942 A MX 2021015942A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- cns disorders
- treating cns
- ilib
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J61/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one or two atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/002—Expansion of ring A by one atom, e.g. A homo steroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962867618P | 2019-06-27 | 2019-06-27 | |
| PCT/US2020/040153 WO2020264509A1 (en) | 2019-06-27 | 2020-06-29 | Compositions and methods for treating cns disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021015942A true MX2021015942A (es) | 2022-04-18 |
Family
ID=71728947
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021015942A MX2021015942A (es) | 2019-06-27 | 2020-06-29 | Composiciones y métodos para tratar trastornos del snc. |
| MX2024009926A MX2024009926A (es) | 2019-06-27 | 2021-12-16 | Composiciones y metodos para tratar trastornos del snc. |
| MX2024009925A MX2024009925A (es) | 2019-06-27 | 2021-12-16 | Composiciones y metodos para tratar trastornos del snc. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024009926A MX2024009926A (es) | 2019-06-27 | 2021-12-16 | Composiciones y metodos para tratar trastornos del snc. |
| MX2024009925A MX2024009925A (es) | 2019-06-27 | 2021-12-16 | Composiciones y metodos para tratar trastornos del snc. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12552829B2 (https=) |
| EP (1) | EP3990469A1 (https=) |
| JP (2) | JP7787635B2 (https=) |
| KR (1) | KR20220038680A (https=) |
| CN (1) | CN114391019A (https=) |
| AR (1) | AR119305A1 (https=) |
| AU (1) | AU2020302748A1 (https=) |
| BR (1) | BR112021026462A2 (https=) |
| CA (1) | CA3143509A1 (https=) |
| IL (1) | IL289172A (https=) |
| MX (3) | MX2021015942A (https=) |
| TW (1) | TWI896547B (https=) |
| WO (1) | WO2020264509A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015002252A (es) | 2012-08-21 | 2015-07-21 | Sage Therapeutics Inc | Metodos para tratar epilepsia o estado de epilepsia. |
| JP6470258B2 (ja) | 2013-04-17 | 2019-02-13 | セージ セラピューティクス， インコーポレイテッド | １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| TWI904593B (zh) | 2016-08-23 | 2025-11-11 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| EP3720867A1 (en) | 2017-12-08 | 2020-10-14 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
| CR20240234A (es) | 2019-05-31 | 2024-07-09 | Sage Therapeutics Inc | ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629) |
| JP7787635B2 (ja) * | 2019-06-27 | 2025-12-17 | セージ セラピューティクス， エルエルシー | Ｃｎｓ障害を治療するための組成物及び方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2969M (fr) | 1963-05-22 | 1964-11-30 | Roussel Uclaf | Nouveau médicament notamment pour le traitement des spasmes d'origine coronarienne on viscérale. |
| ES432106A1 (es) | 1973-11-30 | 1976-11-01 | Schering Ag | Procedimiento para la preparacion de d-homo-20-cetopregna- nos. |
| IL48628A0 (en) | 1974-12-23 | 1976-02-29 | Schering Ag | D-homo-20-keto-pregnanes and process for their manufactur |
| GB1570394A (en) | 1976-01-06 | 1980-07-02 | Glaxo Lab Ltd | 11-acyloxy-3-hydroxy steroids |
| US4060295A (en) | 1976-03-15 | 1977-11-29 | Molex Incorporated | Zero insertion force printed circuit board edge connector assembly |
| GB1581234A (en) | 1976-04-05 | 1980-12-10 | Glaxo Operations Ltd | 11a - amino - 3a - hydroxysteroids |
| GB1581235A (en) | 1977-04-04 | 1980-12-10 | Glaxo Operations Ltd | 11a-amino-3a-hydroxy-steroids |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| FI972202L (fi) | 1994-11-23 | 1997-07-17 | Cocensys Inc | Androstaanit ja pregnaanit GABA-reseptoreiden allosteeriseen muunteluun |
| AU3967297A (en) | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| WO2005105822A2 (en) * | 2004-04-23 | 2005-11-10 | Euro-Celtique S.A. | 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
| CN101585862B (zh) * | 2008-05-20 | 2014-12-17 | 梅克芳股份公司 | 甾族化合物 |
| HRP20230747T1 (hr) | 2011-09-08 | 2024-01-05 | Sage Therapeutics, Inc. | Neuroaktivni steroidi, pripravci i njihova uporaba |
| JP6470258B2 (ja) | 2013-04-17 | 2019-02-13 | セージ セラピューティクス， インコーポレイテッド | １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| HRP20201126T1 (hr) | 2014-05-29 | 2020-12-11 | Sage Therapeutics, Inc. | Neuroaktivni steroidi, njihovi pripravci i uporabe |
| US10577390B2 (en) | 2014-10-16 | 2020-03-03 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| WO2017049044A1 (en) | 2015-09-16 | 2017-03-23 | Bartolucci Giampiero | Ursodeoxycholic acid and brain disorders |
| HK1258616A1 (zh) | 2016-03-08 | 2019-11-15 | Sage Therapeutics, Inc. | 神经活性类固醇、组合物、及其用途 |
| US20190233465A1 (en) * | 2016-07-11 | 2019-08-01 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| EP3641779B1 (en) * | 2017-06-23 | 2024-02-28 | The Board of Trustees of the University of Illinois | Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof |
| WO2019041078A1 (en) | 2017-08-28 | 2019-03-07 | Zhejiang Jiachi Pharmaceutical Development Ltd. | ASYMMETRIC SYNTHESIS AND USES OF COMPOUNDS IN TREATMENT OF DISEASES |
| EP3678670A1 (en) * | 2017-09-07 | 2020-07-15 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| CN111741965B (zh) | 2017-12-22 | 2024-06-25 | 萨奇治疗股份有限公司 | 治疗中枢神经系统疾病的组合物和方法 |
| CN114656514B (zh) | 2018-02-11 | 2024-05-14 | 江苏豪森药业集团有限公司 | 一种甾族类衍生物调节剂及其制备方法和应用 |
| IL283629B2 (en) * | 2018-12-05 | 2026-03-01 | Sage Therapeutics Inc | Neuroactive steroids and methods of using them |
| CN116589521B (zh) | 2019-01-08 | 2025-07-11 | 成都康弘药业集团股份有限公司 | 甾体类化合物、用途及其制备方法 |
| WO2020210117A1 (en) | 2019-04-08 | 2020-10-15 | Athenen Therapeutics, Inc. | Steroids with altered pharmacokinetic properties and methods of use thereof |
| WO2020210116A1 (en) | 2019-04-08 | 2020-10-15 | Athenen Therapeutics, Inc. | Steroids with altered pharmacokinetic properties and methods of use thereof |
| CR20240234A (es) | 2019-05-31 | 2024-07-09 | Sage Therapeutics Inc | ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629) |
| US20230257415A1 (en) | 2019-06-27 | 2023-08-17 | Sage Therapeutics, Inc. | Compounds for treating cns disorders |
| JP7787635B2 (ja) | 2019-06-27 | 2025-12-17 | セージ セラピューティクス， エルエルシー | Ｃｎｓ障害を治療するための組成物及び方法 |
| AU2020304673A1 (en) | 2019-06-27 | 2022-01-20 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| WO2022115381A1 (en) * | 2020-11-25 | 2022-06-02 | Sage Therapeutics, Onc. | Compositions and methods for treating cns disorders cross reference to related application |
-
2020
- 2020-06-29 JP JP2021577424A patent/JP7787635B2/ja active Active
- 2020-06-29 TW TW109121938A patent/TWI896547B/zh active
- 2020-06-29 MX MX2021015942A patent/MX2021015942A/es unknown
- 2020-06-29 US US17/620,226 patent/US12552829B2/en active Active
- 2020-06-29 AR ARP200101836A patent/AR119305A1/es unknown
- 2020-06-29 AU AU2020302748A patent/AU2020302748A1/en active Pending
- 2020-06-29 CA CA3143509A patent/CA3143509A1/en active Pending
- 2020-06-29 WO PCT/US2020/040153 patent/WO2020264509A1/en not_active Ceased
- 2020-06-29 BR BR112021026462A patent/BR112021026462A2/pt unknown
- 2020-06-29 EP EP20743476.2A patent/EP3990469A1/en active Pending
- 2020-06-29 CN CN202080059463.9A patent/CN114391019A/zh active Pending
- 2020-06-29 KR KR1020227002448A patent/KR20220038680A/ko active Pending
-
2021
- 2021-12-16 MX MX2024009926A patent/MX2024009926A/es unknown
- 2021-12-16 MX MX2024009925A patent/MX2024009925A/es unknown
- 2021-12-20 IL IL289172A patent/IL289172A/en unknown
-
2025
- 2025-01-05 JP JP2025000024A patent/JP2025060984A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024009926A (es) | 2024-08-22 |
| US20220380405A1 (en) | 2022-12-01 |
| CA3143509A1 (en) | 2020-12-30 |
| TW202114700A (zh) | 2021-04-16 |
| BR112021026462A2 (pt) | 2022-03-15 |
| AU2020302748A1 (en) | 2022-01-06 |
| KR20220038680A (ko) | 2022-03-29 |
| WO2020264509A1 (en) | 2020-12-30 |
| MX2024009925A (es) | 2024-08-22 |
| JP7787635B2 (ja) | 2025-12-17 |
| CN114391019A (zh) | 2022-04-22 |
| US12552829B2 (en) | 2026-02-17 |
| JP2022538299A (ja) | 2022-09-01 |
| EP3990469A1 (en) | 2022-05-04 |
| US20230303616A9 (en) | 2023-09-28 |
| TWI896547B (zh) | 2025-09-11 |
| JP2025060984A (ja) | 2025-04-10 |
| AR119305A1 (es) | 2021-12-09 |
| IL289172A (en) | 2022-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021015942A (es) | Composiciones y métodos para tratar trastornos del snc. | |
| MX2023002004A (es) | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. | |
| MX2020006599A (es) | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. | |
| MX2025008327A (es) | Composiciones y metodos para el tratamiento de trastornos del snc | |
| SA522432955B1 (ar) | Kras g12c مثبطات | |
| PH12021500049A1 (en) | 2,3-dihydroquinazolin compounds as nav1.8 inhibitors | |
| PH12019550140A1 (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| MX2022012317A (es) | Oxisteroles y metodos de uso de los mismos. | |
| MX2021015854A (es) | Composiciones y métodos para tratar trastornos del snc. | |
| PH12017501326A1 (en) | Tgf-� inhibitors | |
| MX2023006063A (es) | Composiciones y metodos para el tratamiento de trastornos del sistema nervioso central. | |
| EP4484440A3 (en) | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders | |
| MX2022004450A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1. | |
| ZA202007566B (en) | 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof | |
| MX2016016530A (es) | Inhibidores de fosfatidilinositol 3-quinasa. | |
| PH12017501422A1 (en) | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders | |
| MX2009009466A (es) | Compuestos triciclicos de utilidad en el tratamiento de trastornos del hierro. | |
| MX2021007258A (es) | Composiciones de esparsentan amorfas. | |
| PH12020551343A1 (en) | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer | |
| PH12021552953A1 (en) | Tricyclic compounds | |
| SG11201907945YA (en) | Azetidine derivative | |
| MX2021003508A (es) | Derivados de 5-azaindazol como antagonistas del receptor de adenosina. | |
| MX2019014321A (es) | Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias. | |
| MX2020009334A (es) | Compuestos para tratar la enfermedad de alzheimer. | |
| MX2024006176A (es) | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno. |